Target intelligence / Profile preview

Ornithine decarboxylase antizyme 1 (OAZ1)

Target
OAZ1
Molecular classification
Enzyme inhibitor, Regulatory protein, Other (Polyamine metabolic regulator)
01

Overview

Ornithine decarboxylase antizyme 1 (OAZ1) is a regulatory protein that controls intracellular levels of polyamines, which are essential for cell growth and proliferation. OAZ1 acts by binding to ornithine decarboxylase (ODC)—the key enzyme in polyamine biosynthesis—and targeting it for ubiquitin-independent degradation via the proteasome, thereby reducing polyamine synthesis. Its own production is regulated by a programmed, polyamine-sensitive ribosomal frameshifting mechanism. OAZ1 also inhibits polyamine uptake into cells and can regulate other proteins involved in differentiation, signal transduction, and cell cycle control. These actions contribute to its tumor suppressor role in several cancers, and altered expression or regulation of OAZ1 can influence various disease states, including cancer, autoimmune and neuropsychiatric conditions[1][2][3][4][5].

Other names
OAZAZ1AZIODC-Azantizyme 1OAZ1_HUMAN
02

Mechanism of action

Promotes ubiquitin-independent proteasomal degradation of ornithine decarboxylase (ODC) Inhibits ODC activity by binding and blocking its dimerization Inhibits cellular polyamine uptake[1][2][4]

03

Biological functions

Regulation of polyamine homeostasisCell cycle regulationNegative regulation of cell proliferationInduction of apoptosisRegulation of cellular differentiationInhibition of polyamine uptakeProteasomal degradation of ornithine decarboxylase
04

Disease associations

Cancer (tumor suppressor activity in various cancers)Autoimmune disorders (e.g., genetic associations with systemic lupus erythematosus)Neuropsychiatric disorders (chromatin changes in brains of suicide completers)Vascular diseases (vascular smooth muscle cell proliferation)
05

Safety considerations

no notable direct safety concerns or therapeutic challenges documented for targeting OAZ1 itself; general risk may involve disruption of normal cell proliferation and homeostasis if polyamine regulation is broadly inhibited[1][3][4]
06

Interacting drugs

none known or approved as direct drugs targeting OAZ1
07

Biomarkers

no established clinical biomarkers for OAZ1 as patient selection or efficacy monitoring tool are reported in current sources[1][3][4]

Beyond the preview

Go deeper on Ornithine decarboxylase antizyme 1 (OAZ1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ornithine decarboxylase antizyme 1 (OAZ1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call